Drug intelligence / Profile preview

F-02-2-Na

Development stage: Phase 1
Lead developer: Novagains Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

F-02-2-Na is an orally administered small molecule URAT1 inhibitor developed by Guangdong Hengqin Novagains Biopharmaceutical for the treatment of hyperuricemia and gout. The drug targets the Solute Carrier Family 22 Member 12 (SLC22A12), also known as Urate Transporter 1 (URAT1), which is primarily expressed in the proximal tubules of the kidney. By inhibiting URAT1, F-02-2-Na prevents the reabsorption of uric acid from the urine into the blood, thereby promoting uric acid excretion and reducing serum urate levels. It is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile, including the impact of food on its bioavailability.

Other names: F-02-2 sodiumF02-2 sodiumF 02-2 sodium

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on F-02-2-Na.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-02-2-Na.

Explore the full profile